Skip to content
10-K

Annual Report

Regulus Therapeutics Inc.

0001628280-25-012627

← back to feed
Filed
Mar 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2024 56.35M sh
Shares Diluted FY 2024 · Dec 31, 2023 18.96M sh
Capex FY 2024 · Dec 31, 2024 $340K
Capex FY 2024 · Dec 31, 2023 $613K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$41.67M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$26.77M
Short Term Debt FY 2024 · Dec 31, 2024 $0
Short Term Debt FY 2024 · Dec 31, 2023 $1.33M
Short Term Investments FY 2024 · Dec 31, 2024 $37.25M
Short Term Investments FY 2024 · Dec 31, 2023 $0
Cash And Equivalents FY 2024 · Dec 31, 2024 $38.53M
Cash And Equivalents FY 2024 · Dec 31, 2023 $23.77M
Stockholders Equity FY 2024 · Dec 31, 2024 $76.41M
Stockholders Equity FY 2024 · Dec 31, 2023 $21.19M
Stockholders Equity FY 2024 · Dec 31, 2022 $33.29M
Current Liabilities FY 2024 · Dec 31, 2024 $7.5M
Current Liabilities FY 2024 · Dec 31, 2023 $8.51M
Total Liabilities FY 2024 · Dec 31, 2024 $7.77M
Total Liabilities FY 2024 · Dec 31, 2023 $9.56M
Current Assets FY 2024 · Dec 31, 2024 $82.35M
Current Assets FY 2024 · Dec 31, 2023 $28.18M
Total Assets FY 2024 · Dec 31, 2024 $84.18M
Total Assets FY 2024 · Dec 31, 2023 $30.75M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.82
Eps Diluted restated FY 2024 · Dec 31, 2023 −$1.58
Eps Basic FY 2024 · Dec 31, 2024 −$0.82
Eps Basic restated FY 2024 · Dec 31, 2023 −$1.58
Sga Expense FY 2024 · Dec 31, 2024 $14.67M
Sga Expense FY 2024 · Dec 31, 2023 $9.96M
Rd Expense FY 2024 · Dec 31, 2024 $35.37M
Rd Expense FY 2024 · Dec 31, 2023 $21.15M
Net Income FY 2024 · Dec 31, 2024 −$46.36M
Net Income FY 2024 · Dec 31, 2023 −$30.04M
Operating Income FY 2024 · Dec 31, 2024 −$50.04M
Operating Income FY 2024 · Dec 31, 2023 −$31.11M